{"data":[{"accessionNo":"0001213900-26-109019","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":"04272N102","securityClass":"Common Stock, $0.0001 Par Value per Share","eventDate":"2026-10-06","reportingPerson":"Vivo Opportunity, LLC","reportingCik":null,"personType":"OO","sharesOwned":2472701,"percentOfClass":5,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001213900-26-109019","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":"04272N102","securityClass":"Common Stock, $0.0001 Par Value per Share","eventDate":"2026-10-06","reportingPerson":"Vivo Opportunity Fund Holdings, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1514446,"percentOfClass":3.1,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001213900-26-109019","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":"04272N102","securityClass":"Common Stock, $0.0001 Par Value per Share","eventDate":"2026-10-06","reportingPerson":"Vivo Opportunity Co-Invest (Cycle 3), L.P.","reportingCik":null,"personType":"PN","sharesOwned":781503,"percentOfClass":1.6,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001213900-26-109019","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":"04272N102","securityClass":"Common Stock, $0.0001 Par Value per Share","eventDate":"2026-10-06","reportingPerson":"Vivo Opportunity Cayman, LLC","reportingCik":null,"personType":"OO","sharesOwned":152971,"percentOfClass":0.3,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001213900-26-109019","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":"04272N102","securityClass":"Common Stock, $0.0001 Par Value per Share","eventDate":"2026-10-06","reportingPerson":"Vivo Opportunity Co-Invest, L.P.","reportingCik":null,"personType":"PN","sharesOwned":176752,"percentOfClass":0.3,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001213900-26-109019","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":"04272N102","securityClass":"Common Stock, $0.0001 Par Value per Share","eventDate":"2026-10-06","reportingPerson":"Vivo Opportunity Cayman Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":152971,"percentOfClass":0.3,"filedAt":"2026-10-13","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0000947871-26-000931","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":"04272N102","securityClass":"Common Stock","eventDate":"2026-10-06","reportingPerson":"ORBIMED ADVISORS LLC","reportingCik":"0001055951","personType":"IA","sharesOwned":2875962,"percentOfClass":5.8,"filedAt":"2026-10-08","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0000947871-26-000931","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":"04272N102","securityClass":"Common Stock","eventDate":"2026-10-06","reportingPerson":"OrbiMed Advisors IV Limited","reportingCik":"0001966835","personType":"CO","sharesOwned":1437981,"percentOfClass":2.9,"filedAt":"2026-10-08","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0000947871-26-000931","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":"04272N102","securityClass":"Common Stock","eventDate":"2026-10-06","reportingPerson":"OrbiMed Asia GP IV, L.P.","reportingCik":"0001966836","personType":"PN","sharesOwned":1437981,"percentOfClass":2.9,"filedAt":"2026-10-08","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0000947871-26-000931","formType":"SCHEDULE 13D/A","amendmentNo":2,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":"04272N102","securityClass":"Common Stock","eventDate":"2026-10-06","reportingPerson":"OrbiMed Capital GP VIII LLC","reportingCik":"0001845804","personType":"OO","sharesOwned":1437981,"percentOfClass":2.9,"filedAt":"2026-10-08","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0002012383-26-002185","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ARRIVENT BIOPHARMA INC","ticker":"AVBP","cusip":"04272N102","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":3182080,"percentOfClass":6.8,"filedAt":"2026-07-27","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0000315066-26-001106","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001868279","issuerName":"ARRIVENT BIOPHARMA INC","ticker":"AVBP","cusip":"04272N102","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":3016131.87,"percentOfClass":6.8,"filedAt":"2026-05-06","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0000315066-26-001106","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001868279","issuerName":"ARRIVENT BIOPHARMA INC","ticker":"AVBP","cusip":"04272N102","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":3016131.87,"percentOfClass":6.8,"filedAt":"2026-05-06","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001104659-26-023750","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent Biopharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock, $0.0001 Par Value per Share","eventDate":"2025-12-31","reportingPerson":"Dr. James I. Healy (\"Healy\")","reportingCik":null,"personType":"IN","sharesOwned":1696752,"percentOfClass":4.1,"filedAt":"2026-03-05","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001104659-26-023750","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent Biopharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock, $0.0001 Par Value per Share","eventDate":"2025-12-31","reportingPerson":"Sofinnova Venture Partners XI, L.P. (\"SVP XI\")","reportingCik":null,"personType":"PN","sharesOwned":1696752,"percentOfClass":4.1,"filedAt":"2026-03-05","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001104659-26-023750","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent Biopharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock, $0.0001 Par Value per Share","eventDate":"2025-12-31","reportingPerson":"Sofinnova Management XI, L.P. (\"SM XI LP\")","reportingCik":null,"personType":"PN","sharesOwned":1696752,"percentOfClass":4.1,"filedAt":"2026-03-05","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001104659-26-023750","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent Biopharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock, $0.0001 Par Value per Share","eventDate":"2025-12-31","reportingPerson":"Sofinnova Management XI, L.L.C. (\"SM XI LLC\")","reportingCik":null,"personType":"OO","sharesOwned":1696752,"percentOfClass":4.1,"filedAt":"2026-03-05","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001104659-26-023750","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent Biopharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock, $0.0001 Par Value per Share","eventDate":"2025-12-31","reportingPerson":"Dr. Maha Katabi (\"Katabi\")","reportingCik":null,"personType":"IN","sharesOwned":1696752,"percentOfClass":4.1,"filedAt":"2026-03-05","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0002058093-26-000004","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"INFINITUM ASSET MANAGEMENT, LLC","reportingCik":null,"personType":"IA","sharesOwned":4123923,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0002058093-26-000004","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Infinitum Partners GP, LLC","reportingCik":null,"personType":"PN","sharesOwned":4123923,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0002058093-26-000004","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Infinitum Cayman Master, Ltd.","reportingCik":null,"personType":"PN","sharesOwned":4123923,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0000902664-26-001013","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Hillhouse Investment Management, Ltd.","reportingCik":null,"personType":"IA","sharesOwned":3929117,"percentOfClass":9.5,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0000102909-26-000090","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent Biopharma Inc","ticker":"AVBP","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":1869266,"percentOfClass":4.52,"filedAt":"2026-01-30","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0002012383-26-000643","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001868279","issuerName":"ARRIVENT BIOPHARMA INC","ticker":"AVBP","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":2319341,"percentOfClass":5.6,"filedAt":"2026-01-21","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001214659-25-016716","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-09-30","reportingPerson":"Ting Jia","reportingCik":null,"personType":"IN","sharesOwned":1971054,"percentOfClass":4.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001214659-25-016716","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-09-30","reportingPerson":"Octagon Capital Advisors LP","reportingCik":null,"personType":"IA,PN","sharesOwned":1971054,"percentOfClass":4.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001214659-25-016716","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-09-30","reportingPerson":"Octagon Private Opportunities Fund LP","reportingCik":null,"personType":"PN,OO","sharesOwned":799911,"percentOfClass":2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001214659-25-016716","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-09-30","reportingPerson":"Octagon Investments Master Fund LP","reportingCik":null,"personType":"PN,OO","sharesOwned":776667,"percentOfClass":1.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001214659-25-016716","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock, $0.0001 par value","eventDate":"2025-09-30","reportingPerson":"Octagon Special Opportunities Fund LP - Series 4","reportingCik":null,"personType":"PN,OO","sharesOwned":394476,"percentOfClass":1,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0000315066-25-002677","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ARRIVENT BIOPHARMA INC","ticker":"AVBP","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":3407549,"percentOfClass":8.4,"filedAt":"2025-11-05","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0000315066-25-002677","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ARRIVENT BIOPHARMA INC","ticker":"AVBP","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":3407549,"percentOfClass":8.4,"filedAt":"2025-11-05","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0000102909-25-000025","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001868279","issuerName":"ArriVent Biopharma Inc","ticker":"AVBP","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":2029531,"percentOfClass":5,"filedAt":"2025-10-30","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0002012383-25-002500","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001868279","issuerName":"ARRIVENT BIOPHARMA INC","ticker":"AVBP","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":2007338,"percentOfClass":4.9,"filedAt":"2025-10-17","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"},{"accessionNo":"0001104659-25-099728","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001868279","issuerName":"ArriVent BioPharma, Inc.","ticker":"AVBP","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-08","reportingPerson":"HBM Healthcare Investments (Cayman) Ltd.","reportingCik":null,"personType":"CO","sharesOwned":2195014,"percentOfClass":5.4,"filedAt":"2025-10-15","canonicalUrl":"https://xoomar.com/markets/stocks/avbp"}],"updatedAt":"2026-11-03T21:19:16.621Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/avbp","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}